COMPOSITION AND METHOD FOR TREATING CORONAVIRUS INFECTION INCLUDING SARS BY ADMINISTRATION OF THERAPEUTICALLY EFFECTIVE AMOUNT OF TYPE I OR TYPE III INTERFERON RECEPTOR AGONIST AND/OR TYPE II INTERFERON RECEPTOR AGONIST

摘要

PURPOSE: A method of treating coronavirus infection including SARS by administration of a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist is provided. It is effective in reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in patients suffering from a coronavirus infection. The composition for treating coronavirus infection including SARS contains a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist. CONSTITUTION: The coronavirus infection including SARS is performed by the step of administration of a therapeutically effective amount of IFN-alpha and IFN-gamma to an individual, in which the individual is exposed to coronavirus and the IFN-alpha and IFN-gamma are administered within 24hr, 48hr or 72hr or 35 days. A Type I or III interferon receptor agonist can be administered daily, twice daily, every other day, twice a week, three times a week. Effective dosages of a Type I interferon receptor agonist can range from about 1 to about 180micrograms. The Type I interferon receptor agonist is IFN-alpha. The IFN-alpha and IFN-gamma are administered subcutaneously in multiple doses. The method of treating a coronavirus infection is effective in reducing the risk that an individual will develop a pathological coronavirus infection, which has clinical sequelae.